Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

14 mars 2023 07h30 HE | Source: Agenus Inc.

Agenus Reports Fourth Quarter and Full Year 2022 Financial Results and Outlines 2023 Objectives

Botensilimab plus balstilimab showed overall response rates of 23% in microsatellite stable colorectal cancer (MSS CRC), 50% in PD-(L)1 refractory non-small cell lung cancer (NSCLC) and in seven...
12 mars 2023 20h29 HE | Source: Agenus Inc.

Agenus Cancels Conference Call to Discuss the Company’s Minority Cash Holdings at SVB in Light of Government’s SVB Deposit Access Announcement

LEXINGTON, Mass., March 12, 2023 (GLOBE NEWSWIRE) -- Agenus (Nasdaq: AGEN), a clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and...
11 mars 2023 11h24 HE | Source: Agenus Inc.

Agenus Schedules Conference Call to Discuss the Company’s Minority Cash Holdings at SVB

LEXINGTON, Mass., March 11, 2023 (GLOBE NEWSWIRE) -- Agenus (Nasdaq: AGEN), a clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and...
28 févr. 2023 07h30 HE | Source: Agenus Inc.

Agenus to Present Botensilimab Data in Oral Plenary Session at the Society of Gynecologic Oncology 2023 Annual Meeting on Women’s Cancer

LEXINGTON, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Agenus (Nasdaq: AGEN), a clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and...
28 févr. 2023 07h30 HE | Source: Agenus Inc.

Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2022 Financial Report

LEXINGTON, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Agenus (Nasdaq: AGEN), an immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced...
26 janv. 2023 07h30 HE | Source: Agenus Inc.

Agenus to Participate in February Investor Conferences

LEXINGTON, Mass., Jan. 26, 2023 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immunological agents targeting cancer and infectious disease, today announced...
23 janv. 2023 07h30 HE | Source: Agenus Inc.

Agenus Presents Clinical Data Demonstrating Durable Responses of Botensilimab/Balstilimab Combination in Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI

Overall response rate (ORR) of 23% and disease control rate (DCR) of 76% in expanded cohort of 70 heavily pre-treated patients; data suggest superior benefit compared to what has been reported for...
10 janv. 2023 08h30 HE | Source: Agenus Inc.

Agenus to Participate at B Riley Securities’ 2023 Virtual Oncology Conference

LEXINGTON, Mass., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Agenus (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline targeting cancer and infectious disease, today announced that Dr. Garo...
21 déc. 2022 08h30 HE | Source: Agenus Inc.

Agenus to Present Botensilimab Data at Late-Breaking Oral Session at ASCO-GI

LEXINGTON, Mass., Dec. 21, 2022 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of therapeutics designed to activate the immune response to...
17 nov. 2022 08h30 HE | Source: Agenus Inc.

Agenus Data at CTOS 2022 Highlight Durable Clinical Responses of Botensilimab / Balstilimab Combination in Advanced Sarcoma

Overall response rate (ORR) of 46% and disease control rate (DCR) of 69% in heavily pre-treated patients who have received a median of 3 prior lines of therapyPatient responses include sarcoma...

Page suivante